In the early days of hemodialysis the base used iO the dialysate was bicarbonate. Its use was quite labor intensive, requiring constant infusion of gaseous C02 to avoid precipitation of calcium and magnesium carbonate. In the mid 1960s Mion et al (1) used acetate dialysate with no evidence of side-effects in six hemodialysis patients and suggested that it could substitute for bicarbonate as the dialysate base. Acetate is metabolized by the liver and skeletal muscles, yielding one mole of bicarbonate for each mole of acetate converted to acetyl CoA. After this single study commercially prepared acetate dialysate became widely utilized as the dialysis procedure became greatly simplified, although there was no direct advantage to the individual patient.
In the mid 1970s several reports suggested that acetate may affect some hemodialysis patients adversely. An "acetate intolerance" syndrome consisting of hyperacetatemia and low bicarbonate levels was reported (2, 3) and implicated as a possible cause for nausea, vomiting, and hypotension occurring during dialysis. These adverse effects became apparent and were probably accentuated at a time when technical changes in dialysis were being made. More efficient dialysis was being performed with higher blood flows and larger dialyzers resulting in a much greater delivery of acetate to the patient. Although some studies reported a higher incidence of intradialytic symptoms and hypotension with rising acetate levels (2, 4) , others found no such relationship between symptoms and acetate levels (5, 6) . This discrepancy suggests that patients may differ in their response to acetate or in their ability to rapidly metabolize large acetate loads (7) .
These reports nonethless prompted a renewal of interest in the use of bicarbonate. They led to major technical advances in dialysis machinery that allowed on-line proportioning of bicarbonate dialysate from concentrate. This requires a more complicated threestream proportioning system (water, bicarbonate con-centrate and an acidified concentrate) in place of the two-stream proportioning of acetate. Its additional cost and complexity deterred its widespread use and led to a host of studies comparing the effects of acetate versus bicarbonate on a number of outcomes such as intradialytic symptoms (8) (9) (10) (11) (12) (13) (14) (15) (16) , hemodynamic stability, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , hypoxemia (9, 18, 19) or the need to give saline or mannitol (13, 15, 16) . Results varied with the patients and dialytic conditions studied.
In the initial comparative study by Graefe et al (8) six hemodialysis patients dialyzed with high efficiency dialysis were selected because they were symptomatic during acetate dialysis. Headaches, nausea, postdialysis fatigue, hypotension, disorientation and dizziness were less frequent (21% vs. 89%) when bicarbonate was used, but there was no report of statistical significance. Patients' concentration ability, measured by a performance test, deteriorated after acetate but not bicarbonate dialysate. It was also possible to use higher ultrafiltration rates when bicarbonate dialysate was utilized. Subsequently other comparative studies were done (9-28), many of which have been discussed in previous reviews on this subject (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
Most of these comparative studies had small sample sizes and were either descriptive or of the cross-over type design, with patients treated at first with acetate and then switched over to bicarbonate. Ideally, the cross-over design assigns patients randomly to acetate or bicarbonate as the initial dialysate, with subsequent cross-over to the alternate dialysate. Blinding of patients and investigators is also desirable, to eliminate bias. These design features are infrequent in the available literature comparing acetate and bicarbonate dialysate. Furthermore, many studies use the dialysis treatments rather than patients as the unit of analysis, which may erroneously increase the power to detect differences in outcomes between the dialysates. Yet despite the methodologic limitations most studies suggest that bicarbonate is advantageous in certain subgroups: patients dialyzed with dialysate sodium less than 140 mEq/L (15, 17, 20) , patients treated with high efficiency dialyzers (8, 12) , patients with frequent symptoms or hypotension on acetate (8, (14) (15) (16) (17) (18) (19) (20) (21) (22) , and patients who are critically ill and have acute renal failure (23) . Improved hemodynamic stability and fewer intradialytic symptoms were most commonly noted in these studies. For this reason, many Authors also recommend using bicarbonate in the elderly or in those with limited cardiac reserve (38, 39) . Bicarbonate may also be preferred in patients with volume overload to allow a higher ultrafiltration rate (8, 11, 24, 25) .
For stable patients treated with dialysate sodium > 138 mEq/L and standard efficiency dialysis, investigators have generally concluded that bicarbonate offers no benefit (27) or at best minor improvements (10, 16) . More recently, Otte et al (28) conducted a prospective double-blind controlled trial, randomizing 16 stable ESRD patients undergoing hemodialysis to receive acetate or bicarbonate dialysate for 3 months and then switching to the alternate dialysate for the next 3 months. They found no difference in intradialytic symptoms or other outcomes. As Otte et al also failed to report the calculated sample size necessary to show a clinically important difference in intradialytic symptoms, one wonders if these studies in stable patients may suffer from a lack of statistical power. The low frequency of events in stable patients requires a large sample to detect clinically important differences. Furthermore, since a "wash-out" period without dialysis therapy is not feasible, the possibility of a carry-over effect may also minimize actual differences and thus contribute to the failure to detect a difference even if one truly does exist.
In view of the high morbidity and mortality of ESRD patients, possible long term effects of acetate are of perhaps even greater importance. Studies addressing such potential consequences have been scarce. Theoretically, acetate dialysate could contribute to hyperphosphatemia (30, 40) and chronic acidosis (11, 14, 16) , both thus worsening renal osteodystrophy (41, 42) . The metabolism of acetate utilizes phosphorus and results in a redistribution of phosphorus into the cell's mitochondria, causing it to be inaccessable for dialytic removal (30, 39) with rebound hyperphosphatemia occurring postdialysis. Dialysis 694 phosphorus removal has been shown to be greater with bicarbonate than with acetate-containing dialysate (43) . Patients dialyzed with acetate tend to be chronically more acidotic, with lower predialysis serum bicarbonate levels than those treated with bicarbonate (11, 14, 16) . A study by Lefebvre et al suggests that correction of predialysis bicarbonate levels to 24 mEq decreases progression of renal osteodystrophy (42) .
Chronic acidosis may also increase muscle catabolism (44) , impair performance during exercise (45) , and inhibit growth in children (46) . An abnormally rapid rate of acetate metabolism may also lead to glucose intolerance, increased lipid synthesis (47, 48) , suppression of thyroid and growth hormone, and increased Iymphokine production (49) causing symptoms of malaise, somnolence, and anorexia. A study by Seyffart et al indicates that nutrition may be improved with bicarbonate dialysate (50) . Heneghan (37) suggests that bicarbonate dialysate may lead to better control of hypertension by allowing higher ultrafiltration rates and more effective fluid removal thus possibly improving long-term survival.
From a scientific point of view it would seem imperative to determine conclusively whether bicarbonate dialysate causes fewer intradialytic symptoms and long-term complications than acetate in the stable ESRD patient, perhaps by means of large longterm prospective randomized controlled trial.
However, for many countries this soon may become irrelevant because more and more patients are utilizing bicarbonate dialysate. This has probably occurred because: 1) many nephrologists believe that bicarbonate dialysate is generally superior; 2) the cost difference between bicarbonate and acetate has narrowed; 3) when updating dialysis machinery, dialysis units purchase equipment that allows one to perform bicarbonate dialysis; and, 4) high efficiency and high flux dialysis requiring bicarbonate dialysate is being performed more frequently to shorten dialysis times and limit personnel costs. (Whether this practice aimed to improve quality of life has adversely affected survival is presently the subject of controversy). According to a poll of major vendors an estimated 80% of hemodialysis patients in the U.S. are now being dialyzed with bicarbonate. In Japan this figure is almost 100% (51) . As this trend continues further experimental studies may be irrelevant and thus not done in those countries. For countries where acetate continues to be widely used, such as in some developing countries, the acetate versus bicarbonate controversy remains alive.
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